<DOC>
	<DOCNO>NCT01557959</DOCNO>
	<brief_summary>This phase II trial study well docetaxel give together cisplatin pegfilgrastim follow erlotinib hydrochloride work treat patient stage IIIB stage IV non-small cell lung cancer . Drugs use chemotherapy , docetaxel cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Colony stimulate factor , pegfilgrastim , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth . Giving dose-dense combination chemotherapy together pegfilgrastim erlotinib hydrochloride may kill tumor cell</brief_summary>
	<brief_title>Docetaxel , Cisplatin , Pegfilgrastim , Erlotinib Hydrochloride Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine regimen improves time-to-progression patient advance non-small cell lung cancer ( NSCLC ) compare historical control . SECONDARY OBJECTIVES : I . To assess response rate median survival . II . To evaluate tumor biomarkers could predict response survival patient treat regimen include endothelial growth factor receptor ( EGFR ) expression , EGFR Fluorescence situ hybridization ( FISH ) , k-ras mutation . III . To evaluate genetic polymorphism marker response survival patient treat regimen include polymorphisms XPD , XRCC1 , XRCC3 , cyclin D1 . OUTLINE : Patients receive docetaxel intravenously ( IV ) 1 hour day 1 , cisplatin IV 1 hour day 1 , pegfilgrastim subcutaneously ( SC ) day 2 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . Beginning 2 week completion docetaxel , cisplatin , pegfilgrastim , patient receive erlotinib hydrochloride orally ( PO ) daily ( QD ) absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Adenocarcinoma , Bronchiolo-Alveolar</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologic Documentation : Either histologic cytologic documentation nonsmall cell carcinoma ( NSCLC ) necessary , follow diagnostic category acceptable : squamous carcinoma , basaloid carcinoma , adenocarcinoma , bronchioloalveolar carcinoma , adenosquamous carcinoma , large cell carcinoma ( neuroendocrine ) , sarcomatoid carcinoma , nonsmall cell carcinoma otherwise specify ( NOS ) ; histologic cytologic documentation recurrence require patient previously completely resect Advanced Disease : Stage IIIB malignant pleural pericardial effusion stage IV disease Patients must ineligible Avastin decline treatment Avastin Prior Treatment : No prior chemotherapy treatment EGFR inhibitor allow ; brain metastasis must control ( patient neurologically stable ) All Patients must Measurable NonMeasurable Disease : measurable disease define least one lesion accurately measure least one dimension ; long diameter measurable lesion must &gt; = 20 mm conventional technique &gt; = 10 mm spiral compute tomography ( CT ) scan ; nonmeasurable disease include follow : Bone lesion Brain metastasis leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal mass confirm followed imaging technique Cystic lesion Tumor lesion situate previously irradiate area Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Granulocytes &gt; = 1,500/ul Platelets &gt; = 100,000/ul Creatinine = &lt; upper limit normal ( ULN ) Bilirubin = &lt; 1.5 mg/dl Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 1.5 x ULN Alkaline ( Alk . ) phosphatase ( phos . ) = &lt; 2.5 x ULN Patients must provide verbal write informed consent participate study Patients pregnant nursing significant risk fetus/infant Patients neuropathy &gt; = grade 2 Patients psychiatric illness would prevent patient give informed consent Patients unable take oral medication Women childbearing potential men sexual partner woman childbearing potential willing practice adequate contraceptive measure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>